pragma.vision Your technology observatory

Verification register Bio, Health & Neuro

Readiness verdict

ANKTIVA (nogapendekin alfa inbakicept)

A dated reading of what is claimed, reported, and independently verified in the current evidence.

As of
2026-06-28
Revision
1
Method
v1.0.0

Current reading

The readiness gap, in one scan

AI-assisted assembly · derived results

Claimed
90

Public ambition and stated capability

Reported
77

Observed practitioner reporting

Verified
59

Independently supported evidence

Gap
+31

Claimed minus verified

Evidence strength Strong

Decision

What the current evidence supports

Human editorial judgment · 2026-06-28

Adopt with guardrails

Why
FDA-approved and now EU-authorized with a strong 71% CR and high bladder-preservation rates, but conditional authorization plus single-arm pivotal design are the guardrails.
Next
Monitor confirmatory/long-term data underpinning the EU conditional authorization and real-world durability beyond the single-arm cohort

Constraints

Blockers

No named blocker is present in the current public projection.

Evidence summary

Derived counts

AI-assisted assembly

Total
6
Tier 1
5
Tier 2
0
Tier 3
1
Supports
4
Contradicts
1
Context
1
Latest observed
2026-02-18

Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.

Publication record

Revisions

Initial public reading

This is the initial public reading. No earlier readiness change is recorded.

Your opinion

Tell us anything.

What works, what doesn't, what's missing — especially about our watches, lenses, and the register itself. Anonymous is fine; leave an email if you'd like a reply.